DOCSLIB.ORG

Environmental Protection Agency § 725.422

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Environmental Protection Agency § 725.422 below in paragraphs (d)(2) through Sequence Source Toxin Name (d)(7) of this section, these comparable Bacillus anthracis Edema factor (Factors I II); toxin sequences, regardless of the orga- Lethal factor (Factors II III) nism from which they are derived, Bacillus cereus Enterotoxin (diarrheagenic must not be included in the introduced toxin, mouse lethal factor) genetic material. Bordetella pertussis Adenylate cyclase (Heat-la- bile factor); Pertussigen (2) Sequences for protein synthesis in- (pertussis toxin, islet acti- hibitor. vating factor, histamine sensitizing factor, Sequence Source Toxin Name lymphocytosis promoting factor) Corynebacterium diphtheriae Diphtheria toxin Clostridium botulinum C2 toxin & C. ulcerans Clostridium difficile Enterotoxin (toxin A) Pseudomonas aeruginosa Exotoxin A Clostridium perfringens Beta-toxin; Delta-toxin Shigella dysenteriae Shigella toxin (Shiga toxin, Shigella dysenteriae type I Escherichia coli & other Heat-labile enterotoxins (LT); toxin, Vero cell toxin) Enterobacteriaceae spp. Heat-stable enterotoxins Abrus precatorius, seeds Abrin (STa, ST1 subtypes ST1a Ricinus communis, seeds Ricin ST1b; also STb, STII) Legionella pneumophila Cytolysin (3) Sequences for neurotoxins. Vibrio cholerae & Vibrio Cholera toxin (choleragen) mimicus Sequence Source Toxin Name (6) Sequences that affect membrane Clostridium botulinum Neurotoxins A, B, C1, D, E, integrity. F, G (Botulinum toxins, botulinal toxins) Sequence Source Toxin Name Clostridium tetani Tetanus toxin (tetanospasmin) Clostridium bifermentans & Lecithinase Proteus mirabilis Neurotoxin other Clostridium spp Staphylococcus aureus Alpha toxin (alpha lysin) Clostridium perfringens Alpha-toxin (phospholipase Yersinia pestis Murine toxin C, lecithinase); Enterotoxin Snake toxins Corynebacterium pyogenes & Cytolysin (phospholipase C), Bungarus caeruleus Caeruleotoxin other Corynebacterium spp. Ovis toxin Bungarus multicinctus Beta-bungarotoxin (sphingomyelinase D) (phospholipase) Staphylococcus aureus Beta-lysin (beta toxin) Crotalus spp. Crotoxin (phospholipase) Dendroaspis viridis Neurotoxin (7) Sequences that are general Naja naja varieties Neurotoxin cytotoxins. Notechia scutatus Notexin (phospholipase) Oxyuranus scutellatus Taipoxin Sequence Source Toxin Name Invertebrate toxins Chironex fleckeri Neurotoxin Adenia digitata Modeccin Androctnus australis Neurotoxin Aeromonas hydrophila Aerolysin (beta-lysin, Centruroides sculpturatus Neurotoxin cytotoxic lysin) Clostridium difficile Cytotoxin (toxin B) (4) Sequences for oxygen labile Clostridium perfringens Beta-toxin; Epsilon-toxin; cytolysins. Kappa-toxin Escherichia coli & other Cytotoxin (Shiga-like toxin, Sequence Source Toxin Name Enterobacteriaceae spp. Vero cell toxin) Pseudomonas aeruginosa Proteases Bacillus alve Alveolysin Staphylococcus aureus Gamma lysin (Gamma toxin); Bacillus cereus Cereolysin Enterotoxins (SEA, SEB, Bacillus laterosporus Laterosporolysin SEC, SED SEE); Bacillus thuringiensis Thuringiolysin Pyrogenic exotoxins A B; Clostridium bifermentans Lysin Toxic shock syndrome tox- Clostridium botulinum Lysin ins (TSST-1) Clostridium caproicum Lysin Staphylococcus aureus & Leucocidin (leukocidin, Clostridium chauvoei Delta-toxin Pseudomonas aeruginosa cytotoxin) Clostridium histolyticum Epsilon-toxin Streptococcus pyogenes Streptolysin S (SLS); Clostridium novyi Gamma-toxin Erythrogenic toxins (scarlet Clostridium oedematiens Delta-toxin fever toxins, pyrogenic Clostridium perfringens Theta-toxin (Perfringolysin) exotoxins) Clostridium septicum Delta-toxin Yersinia enterocolitica Heat-stable enterotoxins (ST) Clostridium sordellii Lysin Clostridium tetani Tetanolysin Listeria monocytogenes Listeriolysin (A B) § 725.422 Physical containment and Streptococcus pneumoniae Pneumolysin control technologies. Streptococcus pyogene Streptolysin O (SLO) The manufacturer must meet all of (5) Sequences for toxins affecting mem- the following criteria for physical con- brane function. tainment and control technologies for 63 VerDate Sep<11>2014 17:03 Aug 08, 2019 Jkt 247184 PO 00000 Frm 00073 Fmt 8010 Sfmt 8010 Q:\40\40V34.TXT PC31 § 725.424 40 CFR Ch. I (7–1–19 Edition) any facility in which the new micro- quirements of § 725.65 and maintains organism will be used for a Tier I ex- records for the initial and subsequent emption; these criteria also serve as uses of the new microorganism that guidance for a Tier II exemption. verify compliance with the following: (a) Use a structure that is designed (i) The certifications made in para- and operated to contain the new micro- graph (b) of this section. organism. (ii) All the eligibility criteria for the (b) Control access to the structure. Tier I exemption including the criteria (c) Provide written, published, and for the recipient microorganism, the implemented procedures for the safety introduced genetic material, the phys- of personnel and control of hygiene. ical containment and control tech- (d) Use inactivation procedures dem- nologies. onstrated and documented to be effec- (b) Certification. To be eligible for the tive against the new microorganism Tier I exemption under this subpart, contained in liquid and solid wastes the manufacturer or importer must prior to disposal of the wastes. The in- submit to EPA a document signed by a activation procedures must reduce via- responsible company official con- ble microbial populations by at least 6 taining the information listed in this logs in liquid and solid wastes. paragraph. (e) Use features known to be effective (1) Name and address of manufac- in minimizing viable microbial popu- turer or importer. lations in aerosols and exhaust gases (2) Date when manufacture or import released from the structure, and docu- is expected to begin. ment use of such features. (3) The identification (genus, species) (f) Use systems for controlling dis- of the recipient microorganism listed semination of the new microorganism in § 725.420 which is being used to create through other routes, and document the new microorganism which will be use of such features. used under the conditions of the Tier I (g) Have in place emergency clean-up exemption. procedures. (4) Certification of the following: (i) Compliance with the introduced § 725.424 Requirements for the Tier I genetic material criteria described in exemption. § 725.421. (a) Conditions of exemption. The manu- (ii) Compliance with the containment facture or import of a new microorga- requirements described in § 725.422, in- nism for commercial purposes is not cluding the provision in paragraph subject to review under this part if all (a)(3) of this section. of the following conditions are met for (5) The site of waste disposal and the all activities involving the new micro- type of permits for disposal, the permit organism: numbers and the institutions issuing (1) The recipient microorganism is the permits. listed in and meets any requirements (6) The certification statement re- specified in § 725.420. quired in § 725.25(b). Certification of (2) The introduced genetic material submission of test data is not required meets the criteria under § 725.421. for the Tier I exemption. (3) The physical containment and control technologies of any facility in § 725.426 Applicability of the Tier I ex- which the microorganism will be man- emption. ufactured, processed, or used meet the The Tier I exemption under § 725.424 criteria under § 725.422. applies only to a manufacturer or im- (4) The manufacturer or importer porter of a new microorganism that submits a certification described in certifies that the microorganism will paragraph (b) of this section to EPA at be used in all cases in compliance with least 10 days before commencing initial §§ 725.420, 725.421, and 725.422. manufacture or import of a new micro- organism derived from a recipient § 725.428 Requirements for the Tier II microorganism listed in § 725.420. exemption. (5) The manufacturer or importer The manufacturer or importer of a complies with the recordkeeping re- new microorganism for commercial 64 VerDate Sep<11>2014 17:03 Aug 08, 2019 Jkt 247184 PO 00000 Frm 00074 Fmt 8010 Sfmt 8010 Q:\40\40V34.TXT PC31.
Recommended publications
  • Clostridium Species

    Clostridium Species

    CLOSTRIDIUM SPECIES Prepared by Assit. Prof.Dr. Najdat B. Mahdi clostridia The clostridia are large anaerobic, gram-positive, motile rods. Many decompose proteins or form toxins, and some do both. Their natural habitat is the soil or the intestinal tract of animals and humans, where they live as harmless saprophytes. Among the pathogens are the organisms causing botulism, tetanus, gas gangrene, and pseudomembranous colitis diseases :The remarkable ability of clostridia to cause is attributed to their (1) ability to survive adverse environmental conditions through spore formation. (2) rapid growth in a nutritionally enriched, oxygen- deprived environment. (3) production of numerous histolytic toxins, and neurotoxins.and enterotoxins, Morphology & Identification . Spores of clostridia are usually wider than the diameter of the rods in which they are formed. In the various species, the spore is placed centrally, subterminally, or terminally. Most species of clostridia are motile and possess peritrichous flagella . Culture Clostridia are anaerobes and grow under anaerobic conditions; a few species are aerotolerant and will also grow in ambient air. Anaerobic culture conditions . In general, the clostridia grow well on the blood-enriched media used to grow anaerobes and on other media used to culture anaerobes as well. Clostridium botulinum Typical Organisms etiologic agents of botulism are a heterogeneous collection of large (0.6 to 1.4 × 3.0 to 20.2 μm), fastidious, sporeforming, anaerobic rods Clostridium botulinum Clostridium botulinum, which causes botulism, is worldwide in distribution; it is found in soil and occasionally in animal feces. Types are distinguished by the antigenic type of toxins they produce. Spores of the organism are highly resistant to heat, with standing 100 °C for several hours.
  • Rapid and Simultaneous Detection of Ricin, Staphylococcal Enterotoxin B

    Rapid and Simultaneous Detection of Ricin, Staphylococcal Enterotoxin B

    Analyst PAPER View Article Online View Journal | View Issue Rapid and simultaneous detection of ricin, staphylococcal enterotoxin B and saxitoxin by Cite this: Analyst,2014,139, 5885 chemiluminescence-based microarray immunoassay† a a b b c c A. Szkola, E. M. Linares, S. Worbs, B. G. Dorner, R. Dietrich, E. Martlbauer,¨ R. Niessnera and M. Seidel*a Simultaneous detection of small and large molecules on microarray immunoassays is a challenge that limits some applications in multiplex analysis. This is the case for biosecurity, where fast, cheap and reliable simultaneous detection of proteotoxins and small toxins is needed. Two highly relevant proteotoxins, ricin (60 kDa) and bacterial toxin staphylococcal enterotoxin B (SEB, 30 kDa) and the small phycotoxin saxitoxin (STX, 0.3 kDa) are potential biological warfare agents and require an analytical tool for simultaneous detection. Proteotoxins are successfully detected by sandwich immunoassays, whereas Creative Commons Attribution-NonCommercial 3.0 Unported Licence. competitive immunoassays are more suitable for small toxins (<1 kDa). Based on this need, this work provides a novel and efficient solution based on anti-idiotypic antibodies for small molecules to combine both assay principles on one microarray. The biotoxin measurements are performed on a flow-through chemiluminescence microarray platform MCR3 in 18 minutes. The chemiluminescence signal was Received 18th February 2014 amplified by using a poly-horseradish peroxidase complex (polyHRP), resulting in low detection limits: Accepted 3rd September 2014 2.9 Æ 3.1 mgLÀ1 for ricin, 0.1 Æ 0.1 mgLÀ1 for SEB and 2.3 Æ 1.7 mgLÀ1 for STX. The developed multiplex DOI: 10.1039/c4an00345d system for the three biotoxins is completely novel, relevant in the context of biosecurity and establishes www.rsc.org/analyst the basis for research on anti-idiotypic antibodies for microarray immunoassays.
  • The Role of Streptococcal and Staphylococcal Exotoxins and Proteases in Human Necrotizing Soft Tissue Infections

    The Role of Streptococcal and Staphylococcal Exotoxins and Proteases in Human Necrotizing Soft Tissue Infections

    toxins Review The Role of Streptococcal and Staphylococcal Exotoxins and Proteases in Human Necrotizing Soft Tissue Infections Patience Shumba 1, Srikanth Mairpady Shambat 2 and Nikolai Siemens 1,* 1 Center for Functional Genomics of Microbes, Department of Molecular Genetics and Infection Biology, University of Greifswald, D-17489 Greifswald, Germany; [email protected] 2 Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, CH-8091 Zurich, Switzerland; [email protected] * Correspondence: [email protected]; Tel.: +49-3834-420-5711 Received: 20 May 2019; Accepted: 10 June 2019; Published: 11 June 2019 Abstract: Necrotizing soft tissue infections (NSTIs) are critical clinical conditions characterized by extensive necrosis of any layer of the soft tissue and systemic toxicity. Group A streptococci (GAS) and Staphylococcus aureus are two major pathogens associated with monomicrobial NSTIs. In the tissue environment, both Gram-positive bacteria secrete a variety of molecules, including pore-forming exotoxins, superantigens, and proteases with cytolytic and immunomodulatory functions. The present review summarizes the current knowledge about streptococcal and staphylococcal toxins in NSTIs with a special focus on their contribution to disease progression, tissue pathology, and immune evasion strategies. Keywords: Streptococcus pyogenes; group A streptococcus; Staphylococcus aureus; skin infections; necrotizing soft tissue infections; pore-forming toxins; superantigens; immunomodulatory proteases; immune responses Key Contribution: Group A streptococcal and Staphylococcus aureus toxins manipulate host physiological and immunological responses to promote disease severity and progression. 1. Introduction Necrotizing soft tissue infections (NSTIs) are rare and represent a more severe rapidly progressing form of soft tissue infections that account for significant morbidity and mortality [1].
  • Review Cholera Toxin Structure, Gene Regulation and Pathophysiological

    Review Cholera Toxin Structure, Gene Regulation and Pathophysiological

    Cell. Mol. Life Sci. 65 (2008) 1347 – 1360 1420-682X/08/091347-14 Cellular and Molecular Life Sciences DOI 10.1007/s00018-008-7496-5 Birkhuser Verlag, Basel, 2008 Review Cholera toxin structure, gene regulation and pathophysiological and immunological aspects J. Sncheza and J. Holmgrenb,* a Facultad de Medicina, UAEM, Av. Universidad 1001, Col. Chamilpa, CP62210 (Mexico) b Department of Microbiology and Immunology and Gothenburg University Vaccine Research Institute (GUVAX), University of Gçteborg, Box 435, Gothenburg, 405 30 (Sweden), e-mail: [email protected] Received 25 October 2007; accepted 12 December 2007 Online First 19 February 2008 Abstract. Many notions regarding the function, struc- have recently been discovered. Regarding the cell ture and regulation of cholera toxin expression have intoxication process, the mode of entry and intra- remained essentially unaltered in the last 15 years. At cellular transport of cholera toxin are becoming the same time, recent findings have generated addi- clearer. In the immunological field, the strong oral tional perspectives. For example, the cholera toxin immunogenicity of the non-toxic B subunit of cholera genes are now known to be carried by a non-lytic toxin (CTB) has been exploited in the development of bacteriophage, a previously unsuspected condition. a now widely licensed oral cholera vaccine. Addition- Understanding of how the expression of cholera toxin ally, CTB has been shown to induce tolerance against genes is controlled by the bacterium at the molecular co-administered (linked) foreign antigens in some level has advanced significantly and relationships with autoimmune and allergic diseases. cell-density-associated (quorum-sensing) responses Keywords.
  • Biological Toxins Fact Sheet

    Biological Toxins Fact Sheet

    Work with FACT SHEET Biological Toxins The University of Utah Institutional Biosafety Committee (IBC) reviews registrations for work with, possession of, use of, and transfer of acute biological toxins (mammalian LD50 <100 µg/kg body weight) or toxins that fall under the Federal Select Agent Guidelines, as well as the organisms, both natural and recombinant, which produce these toxins Toxins Requiring IBC Registration Laboratory Practices Guidelines for working with biological toxins can be found The following toxins require registration with the IBC. The list in Appendix I of the Biosafety in Microbiological and is not comprehensive. Any toxin with an LD50 greater than 100 µg/kg body weight, or on the select agent list requires Biomedical Laboratories registration. Principal investigators should confirm whether or (http://www.cdc.gov/biosafety/publications/bmbl5/i not the toxins they propose to work with require IBC ndex.htm). These are summarized below. registration by contacting the OEHS Biosafety Officer at [email protected] or 801-581-6590. Routine operations with dilute toxin solutions are Abrin conducted using Biosafety Level 2 (BSL2) practices and Aflatoxin these must be detailed in the IBC protocol and will be Bacillus anthracis edema factor verified during the inspection by OEHS staff prior to IBC Bacillus anthracis lethal toxin Botulinum neurotoxins approval. BSL2 Inspection checklists can be found here Brevetoxin (http://oehs.utah.edu/research-safety/biosafety/ Cholera toxin biosafety-laboratory-audits). All personnel working with Clostridium difficile toxin biological toxins or accessing a toxin laboratory must be Clostridium perfringens toxins Conotoxins trained in the theory and practice of the toxins to be used, Dendrotoxin (DTX) with special emphasis on the nature of the hazards Diacetoxyscirpenol (DAS) associated with laboratory operations and should be Diphtheria toxin familiar with the signs and symptoms of toxin exposure.
  • Biological Toxins As the Potential Tools for Bioterrorism

    Biological Toxins As the Potential Tools for Bioterrorism

    International Journal of Molecular Sciences Review Biological Toxins as the Potential Tools for Bioterrorism Edyta Janik 1, Michal Ceremuga 2, Joanna Saluk-Bijak 1 and Michal Bijak 1,* 1 Department of General Biochemistry, Faculty of Biology and Environmental Protection, University of Lodz, Pomorska 141/143, 90-236 Lodz, Poland; [email protected] (E.J.); [email protected] (J.S.-B.) 2 CBRN Reconnaissance and Decontamination Department, Military Institute of Chemistry and Radiometry, Antoniego Chrusciela “Montera” 105, 00-910 Warsaw, Poland; [email protected] * Correspondence: [email protected] or [email protected]; Tel.: +48-(0)426354336 Received: 3 February 2019; Accepted: 3 March 2019; Published: 8 March 2019 Abstract: Biological toxins are a heterogeneous group produced by living organisms. One dictionary defines them as “Chemicals produced by living organisms that have toxic properties for another organism”. Toxins are very attractive to terrorists for use in acts of bioterrorism. The first reason is that many biological toxins can be obtained very easily. Simple bacterial culturing systems and extraction equipment dedicated to plant toxins are cheap and easily available, and can even be constructed at home. Many toxins affect the nervous systems of mammals by interfering with the transmission of nerve impulses, which gives them their high potential in bioterrorist attacks. Others are responsible for blockage of main cellular metabolism, causing cellular death. Moreover, most toxins act very quickly and are lethal in low doses (LD50 < 25 mg/kg), which are very often lower than chemical warfare agents. For these reasons we decided to prepare this review paper which main aim is to present the high potential of biological toxins as factors of bioterrorism describing the general characteristics, mechanisms of action and treatment of most potent biological toxins.
  • Medical Management of Biological Casualties Handbook

    Medical Management of Biological Casualties Handbook

    USAMRIID’s MEDICAL MANAGEMENT OF BIOLOGICAL CASUALTIES HANDBOOK Sixth Edition April 2005 U.S. ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES FORT DETRICK FREDERICK, MARYLAND Emergency Response Numbers National Response Center: 1-800-424-8802 or (for chem/bio hazards & terrorist events) 1-202-267-2675 National Domestic Preparedness Office: 1-202-324-9025 (for civilian use) Domestic Preparedness Chem/Bio Helpline: 1-410-436-4484 or (Edgewood Ops Center – for military use) DSN 584-4484 USAMRIID’s Emergency Response Line: 1-888-872-7443 CDC'S Emergency Response Line: 1-770-488-7100 Handbook Download Site An Adobe Acrobat Reader (pdf file) version of this handbook can be downloaded from the internet at the following url: http://www.usamriid.army.mil USAMRIID’s MEDICAL MANAGEMENT OF BIOLOGICAL CASUALTIES HANDBOOK Sixth Edition April 2005 Lead Editor Lt Col Jon B. Woods, MC, USAF Contributing Editors CAPT Robert G. Darling, MC, USN LTC Zygmunt F. Dembek, MS, USAR Lt Col Bridget K. Carr, MSC, USAF COL Ted J. Cieslak, MC, USA LCDR James V. Lawler, MC, USN MAJ Anthony C. Littrell, MC, USA LTC Mark G. Kortepeter, MC, USA LTC Nelson W. Rebert, MS, USA LTC Scott A. Stanek, MC, USA COL James W. Martin, MC, USA Comments and suggestions are appreciated and should be addressed to: Operational Medicine Department Attn: MCMR-UIM-O U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) Fort Detrick, Maryland 21702-5011 PREFACE TO THE SIXTH EDITION The Medical Management of Biological Casualties Handbook, which has become affectionately known as the "Blue Book," has been enormously successful - far beyond our expectations.
  • TETANUS in ANIMALS — SUMMARY of KNOWLEDGE Malinovská, Z

    TETANUS in ANIMALS — SUMMARY of KNOWLEDGE Malinovská, Z

    DOI: 10.2478/fv-2020-0027 FOLIA VETERINARIA, 64, 3: 54—60, 2020 TETANUS IN ANIMALS — SUMMARY OF KNOWLEDGE Malinovská, Z., Čonková, E., Váczi, P. Department of Pharmacology and Toxicology University of Veterinary Medicine and Pharmacy in Košice, Komenského 73, 041 81 Košice Slovakia [email protected] ABSTRACT the effects of the neurotoxin. The treatment is difficult with an unclear prognosis. Tetanus is a neurologic non-transmissible disease (often fatal) of humans and other animals with a world- Key words: animal; Clostridium tetani; toxin; spasm; wide occurrence. Clostridium tetani is the spore produc- treatment ing bacillus which causes the bacterial disease. In deep penetrating wounds the spores germinate and produce a toxin called tetanospasmin. The main characteristic sign INTRODUCTION of tetanus is a spastic paralysis. A diagnosis is usually based on the clinical signs because the detection in the Of the clostridial neurotoxins, botulinum neurotoxin wound and the cultivation of C. tetani is very difficult. and tetanus neurotoxin are the most potent toxins [15]. Between animal species there is considerable variabili- Their extraordinary toxicity is caused by neurospecificity ty in the susceptibility to the bacillus. The most sensi- and metalloprotease activity, which results in the paralysis. tive animal species to the neurotoxin are horses. Sheep Tetanus is potentially a fatal disease and in some countries and cattle are less sensitive and tetanus in these animal it is still very active. Tetanus is a traumatic clostridiosis, species are less common. Tetanus in cats and dogs are an infection in humans and other animals with worldwide rare and dogs are less sensitive than cats.
  • Biosafety Level 1 and Rdna Training

    Biosafety Level 1 and Rdna Training

    Biosafety Level 1and rDNA Training Office of Biological Safety Biosafety Level 1 and rDNA Training • Difference between Risk Group and Biosafety Level • NIH and UC policy on recombinant DNA • Work conducted at Biosafety Level 1 • UC Code of Conduct for researchers Biosafety Level 1 and rDNA Training What is the difference between risk group and biosafety level? Risk Groups vs Biosafety Level • Risk Groups: Assigned to infectious organisms by global agencies (NIH, CDC, WHO, etc.) • In US, only assigned to human pathogens (NIH) • Biosafety Level (BSL): How the organisms are managed/contained (increasing levels of protection) Risk Groups vs Biosafety Level • RG1: Not associated with disease in healthy adults (non‐pathogenic E. coli; S. cerevisiae) • RG2: Cause diseases not usually serious and are often treatable (S. aureus; Legionella; Toxoplasma gondii) • RG3: Serious diseases that may be treatable (Y. pestis; B. anthracis; Rickettsia rickettsii; HIV) • RG4: Serious diseases with no treatment/cure (Hemorrhagic fever viruses, e.g., Ebola; no bacteria) Risk Groups vs Biosafety Level • BSL‐1: Usually corresponds to RG1 – Good microbiological technique – No additional safety equipment required for biological work (may still need chemical/radiation protection) – Ability to destroy recombinant organisms (even if they are RG1) Risk Groups vs Biosafety Level • BSL‐2: Same as BSL‐1, PLUS… – Biohazard signs – Protective clothing (lab coat, gloves, eye protection, etc.) – Biosafety cabinet (BSC) for aerosols is recommended but not always required – Negative airflow into room is recommended, but not always required Risk Groups vs Biosafety Level • BSL‐3: Same as BSL‐2, PLUS… – Specialized clothing (respiratory protection, Tyvek, etc.) – Directional air flow is required.
  • Penetration of Stratified Mucosa Cytolysins Augment Superantigen

    Penetration of Stratified Mucosa Cytolysins Augment Superantigen

    Cytolysins Augment Superantigen Penetration of Stratified Mucosa Amanda J. Brosnahan, Mary J. Mantz, Christopher A. Squier, Marnie L. Peterson and Patrick M. Schlievert This information is current as of September 25, 2021. J Immunol 2009; 182:2364-2373; ; doi: 10.4049/jimmunol.0803283 http://www.jimmunol.org/content/182/4/2364 Downloaded from References This article cites 76 articles, 24 of which you can access for free at: http://www.jimmunol.org/content/182/4/2364.full#ref-list-1 Why The JI? Submit online. http://www.jimmunol.org/ • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average by guest on September 25, 2021 Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2009 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Cytolysins Augment Superantigen Penetration of Stratified Mucosa1 Amanda J. Brosnahan,* Mary J. Mantz,† Christopher A. Squier,† Marnie L. Peterson,‡ and Patrick M. Schlievert2* Staphylococcus aureus and Streptococcus pyogenes colonize mucosal surfaces of the human body to cause disease. A group of virulence factors known as superantigens are produced by both of these organisms that allows them to cause serious diseases from the vaginal (staphylococci) or oral mucosa (streptococci) of the body.
  • NEUROCHEMISTRY A4b (1)

    NEUROCHEMISTRY A4b (1)

    NEUROCHEMISTRY A4b (1) Neurochemistry Last updated: April 20, 2019 CLASSIFICATION OF NEUROTRANSMITTERS ............................................................................................ 2 CATECHOLAMINES .................................................................................................................................. 3 NORADRENALINE (S. NOREPINEPHRINE, LEVARTERENOL) ..................................................................... 4 EPINEPHRINE .......................................................................................................................................... 6 DOPAMINE ............................................................................................................................................. 6 SEROTONIN (S. 5-HYDROXYTRYPTAMINE, 5-HT) ................................................................................... 8 HISTAMINE ............................................................................................................................................. 10 ACETYLCHOLINE ................................................................................................................................... 11 AMINO ACIDS ......................................................................................................................................... 13 GLUTAMATE, ASPARTATE .................................................................................................................... 13 Γ-AMINOBUTYRIC ACID (GABA) ........................................................................................................
  • ||||||||III US005562907A United States Patent (19 11 Patent Number: 5,562,907 Arnon 45 Date of Patent: Oct

    ||||||||III US005562907A United States Patent (19 11 Patent Number: 5,562,907 Arnon 45 Date of Patent: Oct

    ||||||||III US005562907A United States Patent (19 11 Patent Number: 5,562,907 Arnon 45 Date of Patent: Oct. 8, 1996 54 METHOD TO PREVENT SIDE-EFFECTS AND Suen et al., "Clostridium argentinense, sp. nov: A Geneti INSENSTIVITY TO THE THERAPEUTIC cally Homogenous Group Composed of All Strains of Clostridium botulinum Toxin Type G and Some Nontoxi USES OF TOXINS genic Strains Previously Identified as Clostridium subtermi (76) Inventor: Stephen S. Arnon, 9 Fleetwood Ct., naleor Clostridium hastiforme' Int. J. System. Bacteriol. Orinda, Calif. 94563 (1988) 38(4):375-381. Van Ermengem, "Ueber einem neuen anaeroben Bacillus und seine Beziehungen zum Botulismus' Z. Hyg. Infektion (21) Appl. No.: 254.238 skrankh. (1897) 26:1-56. An English translation can be found in A New Anaerobic Bacillus and Its Relation to (22 Filed: Jun. 6, 1994 Botulism, Rev. Infect. Dis. (1979) 1(4):701-719. Koening et al., "Clinical and Laboratory Observations on Related U.S. Application Data Type E Botulism in Man' Medicine (1964) 43:517-545. Beller et al., “Repeated Type E Botulism in an Alaskan 63 Continuation-in-part of Ser. No. 62,110, May 14, 1993, Eskimo' N. Engl. J. Med. (1990) 322(12):855. abandoned. Schroeder et al., "Botulism from Fermented Trout' T. Nor ske Laegeforen (1962) 82:1084-1086. An English transla 30) Foreign Application Priority Data tion, beyond the title, is currently not available. Mar. 8, 1994 WO) WIPO ..................... PCT/US94/02521 Mandell et al., eds., Principles and Practice of Infectious Diseases, 3rd Edition, Churchill Livingstone, New York, (51 Int. Cl. .......................... A61K 39/08; A61K 39/38; (1990) pp.